查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017497

特發性肺纖維化（IPF）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Idiopathic Pulmonary Fibrosis (IPF) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國市場預計將從約 2.1 億美元成長到約 4.15 億美元（年複合成長率約 7%）。
  • 雖然抗纖維化療法和診斷技術的進步推動了成長，但對根治性治療的需求仍然沒有得到滿足。

特發性肺纖維化（IPF）概述

特發性肺纖維化（IPF）是一種病因不明的慢性進行性間質性肺部疾病，其特徵是肺實質不可逆性纖維化，高解析度CT或組織病理學檢查顯示典型的間質性肺炎（UIP）模式。此病主要影響60歲以上的成年人，是特發性間質性肺炎中最嚴重的類型之一。

臨床上，特發性肺纖維化（IPF）表現為進行進行性勞力性呼吸困難及持續性乾咳，聽診時可聞及特徵性的「尼龍搭扣樣」吸氣性囉音。此病以持續性上皮損傷、創傷治療異常和纖維化過度沉積為特徵，導致肺功能下降和氣體交換受損。

特發性肺纖維化（IPF）的病程呈持續進展性，常伴隨急性加重，預後不良，存活期縮短。雖然抗纖維化療法（例如Pirfenidone、尼達尼布）可以延緩疾病進展，但無法逆轉纖維化，肺移植仍是合格的患者唯一的根治性治療方法。

主要亮點

  • 特發性肺纖維化是進行性、高度致命的纖維性肺病，治療選擇有限。
  • 英國確診病例數預計將從約 38,700 例增加到約 49,100 例（年複合成長率約 2.4%）。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興療法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • PureTech
  • AbbVie
  • Mediar Therapeutics
  • Tvardi Therapeutics, Incorporated
  • Contineum Therapeutics
  • Calluna Pharma AS
  • Haisco Pharmaceutical Group Co., Ltd.
  • Boehringer Ingelheim
  • Syndax Pharmaceuticals
  • Cumberland Pharmaceuticals
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb
  • Arrowhead Pharmaceuticals
  • Rein Therapeutics
  • Regend Therapeutics
  • Trevi Therapeutics
  • Vicore Pharma AB
  • Actelion
  • Daewoong Pharmaceutical Co. LTD.
  • Overseas Pharmaceuticals, Ltd.
  • Pliant Therapeutics, Inc.
  • Chiesi Farmaceutici SpA
  • Bridge Biotherapeutics, Inc.
  • GlaxoSmithKline
  • HuniLife Biotechnology, Inc.
  • Endeavor Biomedicines, Inc.
  • siRNAgen Therapeutics Inc.
  • Genosco Inc.
  • SPARK Biopharma
  • Dragonboat Biopharmaceutical Company Limited
  • Mannkind Corporation
  • Beijing Tide Pharmaceutical Co., Ltd
  • Shanghai Synvida Biotechnology Co.,Ltd.
  • Guangdong Raynovent Biotech Co., Ltd
  • Avalyn Pharma Inc.
  • InSilico Medicine Hong Kong Limited
  • MediciNova
  • GRI Bio Operations, Inc.
  • Nerre Therapeutics Ltd.
  • Sunshine Lake Pharma Co., Ltd.
  • United Therapeutics
  • Melius Pharma AB
  • Pulmongene Ltd.
  • Agomab Spain SL

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前療法
    • 重點
    • 診斷和治療過程/演算法
    • 主要療法概述及KOL洞察
  • 新興療法
    • 重點
    • 值得關注的後期新療法—概述、市場上市預期和KOL洞察
    • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興療法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Idiopathic Pulmonary Fibrosis (IPF) Market Outlook

Thelansis's "Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Pulmonary Fibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology, characterized by irreversible fibrosis of lung parenchyma and a usual interstitial pneumonia (UIP) pattern on high-resolution CT or histopathology. It primarily affects adults over the age of 60 and is one of the most severe forms of idiopathic interstitial pneumonias.

Clinically, IPF presents with progressive exertional dyspnea and persistent dry cough, along with characteristic "Velcro-like" inspiratory crackles on auscultation. The disease is marked by ongoing epithelial injury, aberrant wound healing, and excessive fibrotic deposition, leading to declining lung function and impaired gas exchange.

IPF follows a relentlessly progressive course, often punctuated by acute exacerbations, and is associated with poor prognosis and reduced survival. While antifibrotic therapies (e.g., pirfenidone and nintedanib) can slow disease progression, they do not reverse fibrosis, and lung transplantation remains the only definitive treatment in eligible patients.

Key Highlights

  • IPF is a progressive, high-mortality fibrotic lung disease with limited therapeutic options
  • UK diagnosed prevalence expected to increase from ~38.7K to ~49.1K (~2.4% CAGR)

Market Overview

  • Germany market projected to grow from ~$210M to ~$415M (~7% CAGR)
  • Growth driven by antifibrotic therapies and improved diagnosis, with ongoing unmet need for curative treatments

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • PureTech
  • AbbVie
  • Mediar Therapeutics
  • Tvardi Therapeutics, Incorporated
  • Contineum Therapeutics
  • Calluna Pharma AS
  • Haisco Pharmaceutical Group Co., Ltd.
  • Boehringer Ingelheim
  • Syndax Pharmaceuticals
  • Cumberland Pharmaceuticals
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb
  • Arrowhead Pharmaceuticals
  • Rein Therapeutics
  • Regend Therapeutics
  • Trevi Therapeutics
  • Vicore Pharma AB
  • Actelion
  • Daewoong Pharmaceutical Co. LTD.
  • Overseas Pharmaceuticals, Ltd.
  • Pliant Therapeutics, Inc.
  • Chiesi Farmaceutici S.p.A.
  • Bridge Biotherapeutics, Inc.
  • GlaxoSmithKline
  • HuniLife Biotechnology, Inc.
  • Endeavor Biomedicines, Inc.
  • siRNAgen Therapeutics Inc.
  • Genosco Inc.
  • SPARK Biopharma
  • Dragonboat Biopharmaceutical Company Limited
  • Mannkind Corporation
  • Beijing Tide Pharmaceutical Co., Ltd
  • Shanghai Synvida Biotechnology Co.,Ltd.
  • Guangdong Raynovent Biotech Co., Ltd
  • Avalyn Pharma Inc.
  • InSilico Medicine Hong Kong Limited
  • MediciNova
  • GRI Bio Operations, Inc.
  • Nerre Therapeutics Ltd.
  • Sunshine Lake Pharma Co., Ltd.
  • United Therapeutics
  • Melius Pharma AB
  • Pulmongene Ltd.
  • Agomab Spain S.L.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)